Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "ED"

11234 News Found

Zydus boosts companion diagnostics with AI-powered CGM Diasens and GlucoLive launch
Medical Device | March 12, 2026

Zydus boosts companion diagnostics with AI-powered CGM Diasens and GlucoLive launch

Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care


Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio
News | March 12, 2026

Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio

The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth


NewcelX and Eledon join forces to advance potential Type 1 diabetes cure
News | March 12, 2026

NewcelX and Eledon join forces to advance potential Type 1 diabetes cure

The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets


UK pushes space-made medicines from orbit to patients with new support package
R&D | March 10, 2026

UK pushes space-made medicines from orbit to patients with new support package

The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth


Lifecore Biomedical teams up with Indomo to advance at-home acne therapy
Biopharma | March 10, 2026

Lifecore Biomedical teams up with Indomo to advance at-home acne therapy

Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation


Lilly expands affordable access to diabetes & obesity medicines under new medicare programme
Supply Chain | March 10, 2026

Lilly expands affordable access to diabetes & obesity medicines under new medicare programme

Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans


DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
Clinical Trials | March 09, 2026

DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial

DiaMedica said it plans to launch the trial later in 2026